TANFAC Q2 FY27: 37% revenue growth outpaces 11% PAT growth as margins compress
PAT +10.76% YoY · revenue +36.63% · margins compressing
₹230.48 Cr
+36.63% YoY
₹19.03 Cr
+10.76% YoY
8.12%
-2pp YoY
₹8.93
TANFAC Industries posted standalone Q2 FY27 revenue from operations of ₹230.48 Cr, up 36.6% YoY and 23.1% QoQ, its strongest topline print in recent quarters. But profit after tax of ₹19.03 Cr grew only 10.8% YoY (+12.9% QoQ) — a sharp divergence from the revenue trend, with no exceptional items on either side to explain the gap. We have no analyst/street estimates on record for this quarter and could not locate brokerage previews for TANFAC's Q2 FY27 print, so vsStreet is unknown.
Q2 FY-2027 vs prior quarters
The gap is a margin story. Operating margin (OPM) fell to 11.84% from 15.93% a year ago and 15.27% last quarter, as raw material costs rose 49.4% YoY (faster than the 36.6% revenue growth) and power & fuel costs jumped 62.9% YoY — both outrunning the topline. Net profit margin slipped to 8.12% from 10.15% YoY. Finance costs more than doubled, up 115.6% YoY to ₹1.68 Cr, as the company drew fresh long-term borrowings (₹66.11 Cr non-current debt on the books versus nil a year ago) to fund its capex programme; depreciation rose 24.8% YoY on the same build-out. This measures well short of management's own FY27 guidance of 21-22% blended EBITDA margin (given at the August 2026 concall) — Q2 OPM of 11.84% and H1 OPM of ~13.4% are roughly 800-1000 bps below that target, with H1 revenue growth of ~21% YoY also trailing the guided 30% full-year pace. Management tied the margin ramp to the HFC-32 plant, which is only guided to commission end-November 2026, so the shortfall through H1 is consistent with — not necessarily a reversal of — that plan, but it is a clear gap against the number management put out.
The stock went into the print at ₹3,429.1, up 6% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
FY27 30% revenue growth, FY28 60%+ growth. FY27 EBITDA margins 21-22% blended; FY28 ~25% once HFC-32 operational. HFC-32 commissioning Nov-end; 65% capacity pre-contracted. ₹1,500-1,700 Cr capex over 4 years.
— This quarter: missed
The quarter's corporate activity was capital-raising, not operating: TANFAC completed a ~₹247 Cr QIP (12,58,918 shares at ₹1,965.83, allotted June 2026) and a ~₹99.4 Cr preferential allotment (4,24,847 shares at ₹2,341, allotted September 2026, listed October 8-9, 2026), together funding part of the ₹1,500-1,700 Cr multi-year capex plan behind the new 20,000 MTPA fluorinated product plant. Capital work-in-progress jumped to ₹153.0 Cr from ₹28.5 Cr at FY26-end, and ₹68.08 Cr plus ₹75.55 Lakh of raise proceeds were still sitting in escrow/fixed deposits as of September 30, 2026, pending utilisation per the filing's notes. EPS of ₹8.93 rose only 3.7% YoY despite 10.8% PAT growth, diluted by the roughly 8.4% increase in share count from the two raises. No management press release accompanying this result was available in our records, so the company's own framing of the quarter could not be cross-checked here.
W1
HFC-32 commissioning, guided for end-November 2026, and the subsequent margin ramp toward management's 21-22% FY27 / ~25% FY28 blended EBITDA margin guidance — current OPM of 11.84% is well below this
W2
Finance cost trajectory as further capex-linked borrowings are drawn against the ₹1,500-1,700 Cr multi-year capex plan — already up 115.6% YoY this quarter
W3
Utilisation of the ~₹350 Cr QIP + preferential proceeds (₹68.08 Cr + ₹75.55 Lakh still in escrow/FD as of September 30, 2026) and further EPS dilution from share issuance
Figures converted from ₹ Lakhs (source statement) to ₹ Crore. Standalone only — no consolidated statement in this filing (TANFAC has no subsidiaries). No exceptional items either period. Total income and PAT checks match exactly; previous-quarter and year-ago figures match comparison context to the rupee.
Revenue surge masks margin miss; HFC-32 execution key
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Revenue guidance raised (30% → 35%-40%), but margin guidance materially cut (21-22% → 16% FY27). H1 PAT flat vs 21% growth shows guidance credibility at risk.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
TANFAC delivered strong Q2 revenue growth (36.6% YoY) and raised full-year guidance to 35%-40%, but OPM compressed to 11.8% vs prior 16%-19% expectation, and EBITDA margin guidance cut to 16% from 21-22%. H1 PAT was flat despite 21% revenue growth, signaling margin headwinds outpacing top-line strength. HFC-32 commissioning in Q3 and new product commercialization Dec-Jan are binary catalysts for H2 recovery, but execution risk is high. Valuation warrants hold pending H2 proof.
₹230.5 Cr
Revenue · +36.6% YoY₹19 Cr
Reported PAT · +10.8% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Q2 highest quarterly revenue ~₹230 Cr, 37% YoY growth
METDelivered ₹230.5 Cr, 36.6% YoY; matches claim
Gross profit per ton AHF remained stable; margin % down due to higher realization
METGross profit INR75 Cr vs INR66 Cr YoY (13% up), but margin 32.5% vs 39% YoY; realization-driven mix correct
EBITDA margins normalize to 15%-17% in H2, 16% full-year average
OVERSTATEDPrior guidance 21-22% FY27; new guidance 16% avg is 25% cut; H2 margin dependent on HFC-32 commissioning & cost moderation not yet proven
H1 FY27 revenue grew 21% YoY to ~₹418 Cr
METH1 delivered ₹418 Cr vs ₹345 Cr H1 FY26 (21.1% YoY); matches, but reveals Q1 weakness dragging H1 average
H1 PAT flat at INR36 Cr vs INR36 Cr H1 FY26
METH1 FY27 PAT INR36 Cr vs H1 FY26 INR36 Cr (0% growth); concerning given 21% revenue growth
Earnings quality
What changed since the last call
Revenue guidance raised
UpgradePrior FY27 guidance 30% growth → Revised to 35%-40%; driven by HFC-32 pre-contract demand & solar DHF surge. YoY growth in Q2 at 36.6% sits within new range, validating upside.
EBITDA margin guidance cut
DowngradePrior FY27 guidance 21-22% blended → Revised to 16% average; margin compression from new product ramp (lower pricing in approval stage), HF realization mix, and 45-day cost pass-through lag.
FY28 growth guidance hedged
NeutralPrior FY28 guidance ~60%+ growth → Revised to 55%-60% growth; capped by new product ramp uncertainty and R-32 volume assumptions (expecting 15,000-16,000 MT FY28, but current MOU only 5,000 MT unconverted).
Capex commitment increased (H2 guidance)
NewNew HF plant planned to support HFC-32 and R-32 demand (~13,000-15,000 MT HF consumption from projects). Total capex ₹70-80 Cr FY27 remaining + ₹250 Cr minimum FY28.
The Q&A
Rajesh Gupta (SBI) and Bhavika Singhvi (Niveshaay) pressed hard on margin recovery, skeptical of management's 15%-17% H2 guidance given Q2 miss at 11.8% OPM. Management conceded new product drag and hedged recovery on HFC-32 execution. Meet Vera questioned R-32 volume assumptions; management defended at 2,000-3,000 MT FY27, but MOU conversion pending. Analysts held management accountable; tone defensive.
HFC-32 status & utilization — Meet Gada, Shanghvi Family Office
Answered90% work complete by Sep 26; ₹360 Cr committed (90% of total). Q2 utilization 20%, Q3 95%, FY28+ 90-100%. Commercial production starts Q3.
Margin guidance credibility — Rajesh Gupta, SBI Securities
PartialExpect 15%-17% H2 (not 16%-19% as initially implied). Full-year 16% average due to new products and cost recovery lag. Margins normalize in FY28 to 24%-26% once HFC-32 scales.
R-32 volumes & pricing — Meet Vera, JM Financial
AnsweredFY27: 2,000-3,000 MT. FY28: 3,000-4,000 MT per quarter. Contracted at ~$7, spot $6.8-$7. Pricing moderates to $6.5-$7.5 if costs normalize and capacity online.
Revenue growth breakdown — Harshil Mantri, Mantri Financials
Answered85%-87% from realization/mix (higher product pricing), 12%-15% from volume growth. HF capacity at 78% H1 utilization, 1/3 solar grade.
Margin pressure sources — Bhavika Singhvi, Niveshaay
PartialNew products at lower margin in approval stage. Absolute margin intact, % margin down due to higher realization mix. New product contribution to increase in H2 significantly, with margin expansion.
Cost pass-through lag — Aditya Sahay, Fusion Capital
AnsweredQuarterly or monthly weighted avg pricing. 30-day lag typically. Sulphur +5x YoY (INR25/kg Oct 25 → INR120/kg Sep 26). Company passes on with lag, benefits in subsequent months.
Working capital & fluorospar inventory — Jayesh, Veto Capital
AnsweredFluorospar bulk procurement due to geopolitical risk (3 months → 6-7 months). Creditors increased ₹50 Cr (offset). Temporary measure. Normal inventory in 1-2 quarters post-stabilization. September major revenue month (70% receivable collected Oct).
HFC-32 product commercialization timeline — Karan Kamdar, Choice Institutional
AnsweredTrade market commercial production Dec 2026. OEM segment Jan 2027. Customer qualification ongoing; 2-3 months for approval. Some customers already qualified. MOU (5,000 MT) expected to convert to contract before FY27 year-end.
Geopolitical conflict impact — Karan Kamdar, Choice Institutional
DodgedCurrently favoring India (US antidumping duties on China in refrigerant gases benefit Indian makers). Too early to comment on future; depends on election outcomes and leadership changes.
AHF capacity allocation — Rohit Nagraj, 360 ONE Capital
Answered30,000 MT total AHF (2 plants × 15 MT each); post-debottleneck ~31,000-32,000 MT. Solar: 12,000 MT (increasing to 12,500). R-32: ~13,000-15,000 MT future. Balance (~6,000-8,000 MT) for surface treatment & pharma. New HF plant planned for R-32/HFC demand.
Guidance
FY27 revenue growth 35%-40% (raised from 30%)
MediumQ2 at 36.6% YoY within new range. H1 only 21% YoY (dragged by weak Q1), so H2 must be ~45%+ to hit 35%-40% full-year. Conditional on HFC-32 ramp & new product demand.
FY28 revenue growth 55%-60% vs prior ~60%+ estimate
MediumAssumes HFC-32 full-year utilization + R-32 volumes 15,000-16,000 MT + solar DHF continued ramp. R-32 MOU conversion & commercial scaling key; FY28 growth lower than original 60%+ implies prudence or execution risk.
FY27 EBITDA margin 16% avg (vs prior 21-22% blended guidance)
LowQ2 margin miss (implied EBITDA ~15-16% vs 20%+) suggests H1 average well below target. H2 guided 15%-17% expects recovery from new products scaling & cost moderation. Unproven.
FY28 EBITDA margin 24%-26% (vs prior ~25% estimate)
MediumAssumes HFC-32 commercialization, full-year production, new product margin expansion (from approval stage to normal). New product contribution to grow materially in H2 FY27. Dependent on execution.
FY27 total capex ₹440-450 Cr incl. ₹70-80 Cr remaining for HFC-32 debottleneck & new HF plant
High₹360 Cr already committed for HFC-32; balance ₹30-40 Cr for debottleneck & ₹30-40 Cr for new HF capacity to support HFC-32 & R-32 HF demand.
FY28 capex minimum ₹250 Cr for AHF & solar DHF expansion (exact amount TBD Jan 2027)
MediumPlan to expand AHF from 30k to 45k MT (15k new) & solar DHF from 25k to 50k MT (25k new). Capex amount & timing to be announced; depends on demand validation from H2 FY27.
Risks the call surfaced
Margin compression
HighQ2 OPM 11.8% vs prior guidance 16%-19%; EBITDA margin guidance cut 21-22% → 16% FY27. New product commercialization starting Dec with lower pricing in approval stage. Recovery contingent on volume scaling & cost moderation.
HFC-32 execution risk
High₹360 Cr capex 90% complete by Sep 26; commissioning targeted Q3 FY27 (Nov-Dec 2026). Binary catalyst: if delayed or utilization falls short of 95% Q3 target, H2 revenue guidance (35%-40% FY27) & margin recovery (15%-17% H2) both at risk.
Cost pass-through lag
MediumSulphur price +5x YoY (INR25/kg Oct 25 → INR120/kg Sep 26). Cost pass-through has 30-45 day lag (45 days for solar grade, quarterly/monthly for other segments). If raw material costs spike again, margins compressed for 1-2 months before customer pricing adjusts.
Working capital inflation
LowFluorospar inventory increased ₹50 Cr (3 months → 6-7 months) due to West Asia geopolitical risk & container availability constraints. Working capital days rose 91 → 104 (+13 days). Offset by ₹50 Cr payables increase, but still a temporary cash-flow impact.
R-32 volume & pricing risk
HighFY27 R-32 volumes expected 2,000-3,000 MT (low relative to HFC-32 demand); MOU for 5,000 MT pending contract conversion by FY27 year-end. Pricing contracted at ~$7/kg, spot $6.8-$7; if Chinese capacity comes online (40,000 MT domestic Indian MDC capacity, demand ~400 MT), R-32 pricing could compress to $6-6.5. FY28 volume assumption 15,000-16,000 MT assumes aggressive ramp-up from MOU conversion.
New product commercialization risk
Medium2-3 new fluorinated chemical products (specialty applications: electronics, agro, pharma, aerospace, EVs) launched in Q2-Q3 FY27. Currently in approval/pilot stage with lower margin pricing to penetrate market. Commercial production starts Dec 2026 (trade market), Jan 2027 (OEM segment). Customer qualification ongoing; 2-3 months for approval & samples. Risk: approval delays, customer qualification failures, or inability to scale to normal margins.
Management
Score 6/10. Transparent on challenges (margin miss, WC elevation, cost lags) but hedged on recovery assumptions. Provided detailed cost breakdown & segment mix. Did not fully quantify new product margin impact; evasive on per-unit pricing. CFO candid on adjusted ROE impact from capital raise. HFC-32 project 90% complete on schedule; preferential issue & QIP completed on time. Revenue growth 36.6% YoY validates demand thesis. However, H1 PAT flat vs H1 FY26 despite 21% growth signals operational leverage absent; H2 execution key to validate guidance recovery.
1 · Q3 FY27 (Sep-Dec 2026)
HFC-32 commissioning with 95% utilization target; adds ~₹20-30 Cr revenue run-rate
2 · Dec 2026 onwards
HFC-32 product commercial launch (trade market); OEM segment Jan 2027
3 · Dec 2026-Jan 2027
R-32 MOU (5,000 MT) expected to convert to contract; unlocks firm revenue
Valuation warrants hold pending H2 proof.
Record Revenue, Vanishing Leverage: The Margin Miss That Rewrites FY27
TANFAC delivered its highest-ever quarterly revenue (₹230.5 Cr, +36.6% YoY), but operating margins compressed to 11.8% — a 4.2pp swing down from the prior year and a 4–8pp miss to guidance. The real alarm: H1 net profit is flat despite 21% revenue growth, signaling that cost and product-mix headwinds are overwhelming volume gains.
₹230.5 Cr
+36.6% YoY
11.8%
-4.2pp YoY | vs 16%+ expected
₹36 Cr
0% YoY | despite 21% revenue growth
16%
vs 21–22% prior
The headline looks strong: TANFAC posted its highest quarterly revenue in company history and raised FY27 growth guidance to 35–40% from 30%. On the call, management pointed confidently to new product launches and HFC-32's imminent commissioning. But skip the top line, and the quarter tells a different story. Operating margins are nearly 5 percentage points underwater vs. the prior year. More troubling, H1 net profit is completely flat at ₹36 Cr—the same as H1 FY26—even as revenue grew 21% in the first half. That is not how growth companies behave. The call reveals why, and whether management has a genuine path back to the margin recovery it promises.
The operational leverage went backward
Q2 revenue of ₹230.5 Cr was up 36.6% YoY and 23.1% sequentially—impressive by any measure. But gross profit grew just 8% (₹75 Cr vs ₹66 Cr), and the operating margin collapsed. Management attributes this to three forces: new fluorinated chemical products ramping at lower pricing during customer approval; a product mix shift toward higher-realization (but lower-margin) segments such as solar-grade DHF; and a 30–45 day lag in passing through raw material costs to customers (sulphur is up 5x YoY). Individually, each is credible. Together, they've erased the operating leverage that should come with a 21% H1 revenue surge.
Q2 is highest quarterly revenue, 37% YoY growth
₹230.5 Cr, 36.6% YoY—matches
Supported
Gross profit per ton AHF stable; margin % down due to realization mix
Gross profit ₹75 Cr vs ₹66 Cr YoY, but margin 32.5% vs 39% YoY. Per-ton GP stable, % margin eroded
Supported
H1 FY27 revenue 21% YoY; Q2 revenue highest ever
H1 ₹418 Cr vs ₹345 Cr H1 FY26 (21.1% match). But Q1 weakness dragged average
Supported but masks Q1 weakness
EBITDA margins will normalize to 15–17% in H2, 16% full-year average
Prior guidance 21–22%; new guidance 16% is a 25% cut. Recovery contingent on unproven HFC-32 ramp & cost moderation
Overstated—credibility at risk
H1 PAT flat at ₹36 Cr (same as H1 FY26)
₹36 Cr vs ₹36 Cr H1 FY26 (0% growth)—matches but signals operational headwinds
Supported—but deeply concerning
What changed on this call
Revenue guidance: 30% → 35–40% FY27 (upgrade)
EBITDA margin guidance: 21–22% → 16% FY27 (25% cut)
FY28 revenue: ~60%+ → 55–60% (hedged from prior)
FY28 EBITDA margin: ~25% → 24–26% (slightly lower)
New HF plant capex commitment for H2 (₹30–40 Cr, TBD in Jan 2027)
The upgraded revenue guidance reflects genuine demand pull: HFC-32 pre-contracts now cover 65% of capacity, and solar-grade DHF utilization is 90–95% as Indian solar cell capacity ramps from 30 GW toward 100 GW. But the margin cut is the confession. Management walked back its H2 guidance from the 16–19% range it appeared to imply earlier to a cautious 15–17%, and the full-year EBITDA target dropped from 21–22% to 16%—a material downgrade. This is management admitting that the cost and product-mix headwinds are more persistent than initially flagged.
The bull-bear ledger
Record revenue growth (36.6% YoY) validates demand across all three business lines
HFC-32 project 90% complete; 65% pre-contracted before commissioning—rare de-risking for a capex cycle
Solar-grade DHF is a near-monopoly in India; 30–100 GW capacity tailwind is structural, not cyclical
FY28 EBITDA margin target of 24–26% (once HFC-32 and new products scale) is mechanically achievable if execution holds
R-32 MOU (5,000 MT) pending contract; FY28 volume target 15,000–16,000 MT suggests significant ramp path
H1 net profit flat despite 21% revenue growth signals operational leverage is absent, not delayed
Margin guidance cut (21–22% → 16% FY27) and H2 hedge (15–17%) suggest management confidence eroded as Q2 printed
New product margin recovery unquantified; management relies on assumption that commercialization in Dec–Jan will restore pricing power
Cost pass-through lag (30–45 days for solar grade) means margin remains compressed for 1–2 months if raw material costs spike again
Working capital days up 13 (91 → 104) due to ₹50 Cr fluorospar inventory buildup; temporary cash drag even if offset by payables
HFC-32 is binary: if commissioning delays or utilization misses the 95% Q3 target, H2 guidance collapses
R-32 pricing at ~$7/kg; if Chinese capacity comes online, could compress to $6–6.5, squeezing FY28 uplift assumptions
Ranked risks for a holder
Margin recovery unproven; H1 PAT flat despite 21% revenue growth
HighOperational leverage should kick in as revenue grows. Its absence signals cost or product-mix headwinds are structural, not temporary. If H2 Q3 doesn't show improving margins, FY27 guidance miss is likely.
HFC-32 commissioning and utilization ramp (Q3 binary catalyst)
High65% of capacity is pre-contracted, but operational readiness and commercial execution in Q3 have no margin for error. A delay or utilization miss below 95% would blow through H2 revenue and margin targets.
New product margin drag and commercialization timing
Medium2–3 new fluorinated chemicals launch Dec–Jan at lower margin during approval stage. Management expects contribution to 'increase significantly' in H2, but customer qualification (2–3 months) is not guaranteed on the timeline, and pricing acceptance is unproven.
Cost pass-through lag (30–45 days); raw material volatility
MediumSulphur is up 5x YoY. If costs spike again in the next quarter, margins remain pinched for 1–2 months before customer pricing adjusts. Solar-grade DHF has the longest lag (45 days), so utilization at 90–95% amplifies margin drag if costs move.
R-32 MOU conversion and volume ramp credibility
Medium5,000 MT MOU pending contract (expected 1–1.5 months). FY27 volumes target 2,000–3,000 MT (low); FY28 ramp to 15,000–16,000 MT assumes aggressive scaling and stable pricing. If MOU conversion slips or pricing compresses, FY28 growth target is at risk.
Working capital inflation from geopolitical fluorospar procurement
Low₹50 Cr inventory increase (3 → 6–7 months) due to supply chain risk. Management says it normalizes in 1–2 quarters, but if geopolitical disruptions persist, cash drag extends. Offset partially by ₹50 Cr payables increase, so net impact muted.
How the street is positioned
TANFAC is trading at ₹3,308.05, down 9.3% from its all-time high of ₹3,648 and below both the 20-day (₹3,423) and 50-day (₹3,357) simple moving averages. The stock remains above the 200-day average (₹2,589), so the retreat is a near-term pullback, not a structural breakdown. RSI sits at 45.4—neutral territory, neither oversold nor overbought. The retreat suggests the market is cautiously waiting for proof: revenue beat alone is not enough if margins don't recover.
Institutional positioning shows mixed signals. FII holdings are essentially flat quarter-on-quarter (down 0.01pp to 1.52%), suggesting foreign money is neither adding nor trimming with conviction. Domestic institutions (DII) are slightly more engaged (up 0.63pp to 4.79%), but neither group is aggressively accumulating. Promoter holding is steady at 48.73%—no insider selling near the highs, which is reassuring on confidence but also suggests no new aggressive buyback signal. The market's posture is "show me"—the stock will not re-rate higher until H2 earnings prove that margin recovery is real, not just a hopeful guidance.
The debate
What to watch next
1 · Q3 operating margin
The litmus test. Management guided 15–17% EBITDA margin for H2. If Q3 prints above 14% OPM, margin recovery is on track. Below 13%, and the new product / cost lag headwinds are worse than disclosed. This is the single number that validates or invalidates the guidance.
2 · HFC-32 commissioning and Q3 utilization
Management targeted Q3 95% utilization. Call and result will disclose: (a) if commissioning happened on schedule (Nov–Dec 2026), (b) actual Q3 utilization %. If utilization comes in below 80%, or commissioning slips to Q4, the H2 revenue and margin targets collapse.
3 · New product commercialization and pricing
Management expects 2–3 products to launch in Dec 2026–Jan 2027 with 'significantly increased contribution' in H2. Q4 earnings call (for Q3) should disclose: (a) customer qualifications completed or pending, (b) order book for new products, (c) pricing vs. the approval-stage discounts. If launch is delayed or initial pricing is lower than expected, margin recovery is pushed into FY28.
The number to track
From this quarter forward, watch TANFAC's operating margin trend—not just operating profit, but the percentage. Q2's 11.8% OPM is the floor. Management's credibility hinges on moving that to 14–15% by Q3 and 15–17% for the half. If that doesn't happen, the company is guiding to a number it can't deliver, and the market will punish that when it becomes obvious in H4.
TANFAC delivered a revenue quarter—top-line momentum is real and the HFC-32 strategy is sound. But the operational story is harder. The company is not yet delivering the margin leverage that should come with 36% YoY growth. Management's response—guidance raises on revenue, cuts on margins—is rational, but it reads as a retreat. The margin recovery is credible *if* HFC-32 and new products execute, but "if" is the operative word. For a holder, this is a "hold pending H2 proof" call. For a new buyer, wait for one quarter of evidence that operational leverage is returning—because Q2 showed the opposite.